Entity

Time filter

Source Type

Dublin, Ireland

Opsona Therapeutics is a drug development company specialising in the human immune system and new drugs and vaccines to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases.Based in Ireland, Opsona is a spin-out from Trinity College Dublin . Ireland is ranked highly in the world in immunology research, and TCD has been at the forefront of the field.Opsona's research is primarily focused on the role of Toll-like receptors and TLR signalling in human innate immunity. The company was founded in 2004 by three immunologists:Professor Luke O'NeillProfessor Kingston MillsProfessor Dermot KelleherOpsona's main investors are international and life-science focused:Inventages Venture Capital Seroba Bioventures GenenFund Enterprise Ireland ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ Wikipedia.


Swingler T.E.,University of East Anglia | Kevorkian L.,University of East Anglia | Culley K.L.,University of East Anglia | Illman S.A.,University of Helsinki | And 5 more authors.
Biochemical Journal | Year: 2010

MMP-28 (epilysin) is a recently cloned member of the MMP (matrix metalloproteinase) family. It is highly expressed in the skin by keratinocytes, the developing and regenerating nervous system and a number of other normal human tissues, as well as a number of carcinomas. The MMP28 promoter has previously been cloned and characterized identifying a conserved GT-box that binds Sp1/Sp3 (specificity proteins 1 and 3) proteins and is essential for the basal expression of the gene. The present study demonstrates that MMP28 expression is induced by HDAC (histone deacetylase) inhibitors and that this effect is mediated through theGT-box. Transient transfection assays have shown that the induction of MMP28 expression by the HDAC inhibitior TSA (trichostatin A) is mediated via Sp1 at theGT-box. Immunoprecipitation experiments have shown that the acetylation of Sp1 and Sp3 is increased by TSA treatment; however, no effect on DNA binding was observed. Histone acetyltransferases such as p300 and P/CAF [p300/CREB (cAMP-response-element-binding protein)-binding protein-associated factor] increased induction of the MMP28 promoter by Sp1. Knockdown of HDAC1 using siRNA (small interfering RNA) also induces the MMP28 promoter. Oligonucleotide pulldown identified STRAP (serine/threonine kinase receptor-associated protein) as a further protein recruited to the MMP28 promoter and acting functionally with Sp1. © The Authors. Source


The present invention provides compounds and methods for the treatment and prophylaxis of renal disease and inflammation. In particular the invention provides methods for the treatment of kidney disease and failure through the administration of compounds which function as inhibitors of TLR2 function and expression.


Thomas M.,Roche Holding AG | Kienast Y.,Roche Holding AG | Scheuer W.,Roche Holding AG | Bahner M.,Roche Holding AG | And 12 more authors.
PLoS ONE | Year: 2013

There is increasing experimental evidence for an important role of Angiopoietin-2 (Ang-2) in tumor angiogenesis and progression. In addition, Ang-2 is up-regulated in many cancer types and correlated with poor prognosis. To investigate the functional role of Ang-2 inhibition in tumor development and progression, we generated novel fully human antibodies that neutralize specifically the binding of Ang-2 to its receptor Tie2. The selected antibodies LC06 and LC08 recognize both rodent and human Ang-2 with high affinity, but LC06 shows a higher selectivity for Ang-2 over Ang-1 compared to LC08 which can be considered an Ang-2/Ang-1 cross-reactive antibody. Our data demonstrate that Ang-2 blockade results in potent tumor growth inhibition and pronounced tumor necrosis in subcutaneous and orthotopic tumor models. These effects are attended with a reduction of intratumoral microvessel density and tumor vessels characterized by fewer branches and increased pericyte coverage. Furthermore, anti-Ang-2 treatment strongly inhibits the dissemination of tumor cells to the lungs. Interestingly, in contrast to the Ang-2/Ang-1 cross-reactive antibody LC08 that leads to a regression of physiological vessels in the mouse trachea, the inhibition with the selective anti-Ang-2 antibody LC06 appears to be largely restricted to tumor vasculature without obvious effects on normal vasculature. Taken together, these data provide strong evidence for the selective Ang-2 antibody LC06 as promising new therapeutic agent for the treatment of various cancers. © 2013 Thomas et al. Source


News Article | March 5, 2015
Site: www.fiercebiotech.com

Big Pharma-backed Opsona Therapeutics has looked into its future and seen a possible IPO on the horizon. The Dublin, Ireland-based immunology drug developer made the pronouncement as its lead candidate graduated to the second part of an adaptive Phase II trial. Executives at Opsona have budgeted approximately €8 million ($8.8 million) to trial OPN-305 in around 200 renal transplant recipients that are highly susceptible to early graft dysfunction. Opsona has the cash from its €36 million Series C round--which attracted investment from the VC units of Amgen ($AMGN), Baxter ($BAX), Novartis ($NVS) and Roche ($RHHBY)--to wrap up the Phase IIb trial. But by the time the data roll in late in 2016, Opsona will need to refuel for the next phase. "We might look at a strategic partnership or at an IPO, it will depend on the data we get," Opsona CEO Martin Welschof told the Irish Independent. The data will provide an early hint at whether Opsona can turn its big-name credentials into drug development success. As well as the who's who of big biopharma VCs on its list of investors, Opsona has a trio of scientific founders who command respect in the world of immunology. The founders include the man the Independent describes as Ireland's best-known scientist, professor Luke O'Neill, as well as professors Dermot Kelleher and Kingston Mills. The group spun Opsona out of Trinity College Dublin in 2004 to develop immunomodulating drugs. Opsona's fully-humanized anti-toll-like receptor (TLR) antibody OPN-305 has emerged as the lead candidate. A lot rests on the drug for Opsona--OPN-305 is its only clinical-phase asset--and the healthcare system. If OPN-305 lives up to Opsona's expectations, it could enable surgical teams to transplant organs that would currently be considered borderline. Such organs typically come from donors aged over 60 years old or from people who have complications such as a history of hypertension.


The present invention relates to the identification of a TLR2 binding epitope wherein binding of a binding member to the epitope serves to inhibit TLR2 activation and/or signalling. Polypeptide fragments of TLR2 and three-dimensional structures comprising one or more amino acid residues His318, Pro320, Gln321 or Arg321, Tyr323, Lys347, Phe349, Leu371, Glu375, Tyr376 and His398 of TLR2 which define the identified epitope are provided for use in generating binding members. Also provided are binding members which bind to the identified epitope and methods of using same for the treatment and/or prevention of conditions associated with TLR2 activation and/or signalling.

Discover hidden collaborations